Roivant Sciences(US:ROIV) ZACKS·2025-08-11 13:16分组1 - Roivant Sciences Ltd. reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.23, representing an earnings surprise of +21.74% [1] - Montes Archimedes Acquisition posted revenues of $2.17 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 71.42%, compared to year-ago revenues of $55.13 million [2] - The stock of Montes Archimedes Acquisition has underperformed, losing about 2.9% since the beginning of the year, while the S&P 500 gained 8.6% [3] 分组2 - The current consensus EPS estimate for Montes Archimedes Acquisition is -$0.25 on revenues of $7.59 million for the coming quarter and -$1.01 on revenues of $28.53 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 41% of over 250 Zacks industries, indicating potential underperformance compared to the top 50% [8] - Adherex Technologies Inc., another company in the same industry, is expected to report a quarterly loss of $0.06 per share, with revenues projected at $9.49 million, reflecting a year-over-year increase of 30.7% [9]